Welcome to our dedicated page for Adverum Biotech news (Ticker: ADVM), a resource for investors and traders seeking the latest updates and insights on Adverum Biotech stock.
Adverum Biotechnologies, Inc. reports developments as a clinical-stage biotechnology company focused on intravitreal gene therapy for ocular diseases. Its updates center on ixoberogene soroparvovec, or Ixo-vec, a one-time intravitreal candidate for neovascular, or wet, age-related macular degeneration, including ARTEMIS Phase 3 trial communications and clinical or regulatory disclosures.
Recurring news also includes operating and financial results, inducement equity awards under Nasdaq Listing Rule 5635(c)(4), material agreements, capital-structure matters, shareholder and governance disclosures, and corporate transaction communications.
Adverum Biotechnologies (Nasdaq: ADVM) has granted a stock option for 100,000 shares to a new employee as an inducement under Nasdaq Rule 5635(c)(4). The exercise price is based on the closing sales price on the grant date, and the option will vest over four years, contingent on the employee's continued service. Adverum is focused on gene therapy for ocular diseases, particularly developing ADVM-022 as a one-time treatment for wet age-related macular degeneration.
Adverum Biotechnologies (NASDAQ: ADVM) presented promising results from the OPTIC trial for its gene therapy product, ADVM-022, aimed at treating wet age-related macular degeneration (wet AMD). The study reported an 81%-98% reduction in annual anti-VEGF injections and sustained improvements in mean best-corrected visual acuity (BCVA) and reduced central subfield thickness (CST) for up to two years post-treatment. The Phase 2 LUNA trial is set to begin dosing in Q3 2022, with preliminary data expected throughout 2023.
Adverum Biotechnologies (Nasdaq: ADVM) will present new data from the Phase 1 OPTIC study of ADVM-022 (ixoberogene soroparvovec) for treating wet age-related macular degeneration (wet AMD) at the ASRS 2022 Annual Meeting on July 15, 2022. The presentation will highlight best-corrected visual acuity (BCVA) results and aflibercept protein expression data up to three years post-treatment. Wet AMD affects about 20 million people globally and is a leading cause of blindness in older adults. ADVM-022 offers a one-time IVT injection alternative to frequent anti-VEGF treatments, aiming to improve patient compliance and visual outcomes.
Adverum Biotechnologies has announced the initiation of its Phase 2 LUNA trial for ADVM-022 (ixoberogene soroparvovec) aimed at treating wet age-related macular degeneration (wet AMD). The trial will enroll up to 72 patients and test two dose levels along with enhanced steroid regimens. Cash runway extended into 2025 due to corporate restructuring focused on ADVM-022's clinical development. The LUNA trial aims to build on previous trial successes while evaluating safety and efficacy. Adverum reported $271.1 million in cash as of March 31, 2022.
Adverum Biotechnologies, Inc. (Nasdaq: ADVM) announced that its gene therapy candidate ADVM-022 has received Priority Medicines (PRIME) designation from the European Medicines Agency (EMA) for treating wet age-related macular degeneration (wet AMD). This designation aims to expedite the development of medicines addressing significant unmet needs. ADVM-022 is administered as a one-time intravitreal injection and shows promising results from the OPTIC trial, offering a potential alternative to frequent anti-VEGF injections. A Phase 2 study is planned for Q3 2022.
Adverum Biotechnologies (ADVM) announced new data from the OPTIC study on its gene therapy candidate, ADVM-022, for treating wet age-related macular degeneration (AMD). Findings indicate that aflibercept protein levels remain therapeutically effective for three years after a single dose. The study also reported an 81% reduction in anti-VEGF injections and a 70% decrease in CST fluctuations for patients with specific neutralizing antibody titers. Adverum plans to initiate a Phase 2 study later this year to further evaluate ADVM-022's efficacy and safety.
Adverum Biotechnologies announced new data from the Phase 1 OPTIC study of ADVM-022, a gene therapy for wet AMD, showing therapeutic levels of aflibercept maintained for three years. The study evaluates anatomical outcomes from a single injection of ADVM-022 compared to standard anti-VEGF treatment. Results will be presented at the Macula Society's Annual Meeting on June 9, 2022, highlighting the potential advantages of ADVM-022, such as reduced treatment frequency and improved patient compliance.
Adverum Biotechnologies (Nasdaq: ADVM) presented promising data on its gene therapy pipeline at the 2022 ASGCT Annual Meeting. Highlights include advancements in ADVM-062 for blue cone monochromacy, which has achieved Orphan Drug Designation, and progress towards a Phase 2 trial of ADVM-022 for wet AMD. New proprietary AAV vectors, including LSV1, were showcased for their efficiency in transducing ocular cells. The company is focused on enhancing its AAV manufacturing processes and expanding its research into ocular gene therapy options.
Adverum Biotechnologies announced promising results from its ADVM-022 program for treating wet AMD. Data show that the human equivalent dose of 6E10 vg/eye achieved therapeutic levels of aflibercept in non-human primates (NHPs), supporting plans for a Phase 2 trial in Q3 2022 with doses of 2E11 vg/eye and 6E10 vg/eye. The OPTIC trial indicated an 81% to 94% reduction in annual anti-VEGF injections, depending on neutralizing antibody levels, with no adverse clinical signs noted. These findings pave the way for potential long-term efficacy against wet AMD.
Adverum Biotechnologies, Inc. (Nasdaq: ADVM) reported its Q1 2022 financial results, indicating a net loss of $37.9 million, equating to $0.38 per share. Cash reserves amounted to $271.1 million, expected to last into 2024. The company is on track to initiate a Phase 2 trial for ADVM-022 in wet AMD, with dosing of the first patient planned for Q3 2022. Positive FDA feedback was received regarding the trial, and ADVM-062 received Orphan Drug Designation for blue cone monochromacy.